Douglas W. Blayney

15.3k total citations · 4 hit papers
191 papers, 8.9k citations indexed

About

Douglas W. Blayney is a scholar working on Oncology, Public Health, Environmental and Occupational Health and Economics and Econometrics. According to data from OpenAlex, Douglas W. Blayney has authored 191 papers receiving a total of 8.9k indexed citations (citations by other indexed papers that have themselves been cited), including 96 papers in Oncology, 35 papers in Public Health, Environmental and Occupational Health and 34 papers in Economics and Econometrics. Recurrent topics in Douglas W. Blayney's work include Neutropenia and Cancer Infections (30 papers), Economic and Financial Impacts of Cancer (29 papers) and Cancer Treatment and Pharmacology (29 papers). Douglas W. Blayney is often cited by papers focused on Neutropenia and Cancer Infections (30 papers), Economic and Financial Impacts of Cancer (29 papers) and Cancer Treatment and Pharmacology (29 papers). Douglas W. Blayney collaborates with scholars based in United States, China and Italy. Douglas W. Blayney's co-authors include Richard L. Theriault, Marjorie Robert-Guroff, M. G. Sarngadharan, Joyce C. Niland, David W. Golde, Richard L. Gallo, Isao Miyoshi, Stephen B. Edge, Melissa E. Hughes and Jane C. Weeks and has published in prestigious journals such as Science, New England Journal of Medicine and The Lancet.

In The Last Decade

Douglas W. Blayney

184 papers receiving 8.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A New Subtype of Human T-Cell Leukemia Virus (HTLV-II) Associated with a T-Cell Variant of Hairy Cell Leukemia

1982 894 citations M. G. Sarngadharan, Marjorie Robert-Guroff et al. profile →
Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone Metastases

1996 772 citations Richard L. Theriault, Douglas W. Blayney et al. profile →
Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network

2012 475 citations Melissa E. Hughes, Richard L. Theriault et al. Cancer profile →
American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology

2012 458 citations Douglas W. Blayney et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Douglas W. Blayney

Since Specialization

Citations

This map shows the geographic impact of Douglas W. Blayney's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas W. Blayney with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas W. Blayney more than expected).

Fields of papers citing papers by Douglas W. Blayney

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas W. Blayney. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas W. Blayney. The network helps show where Douglas W. Blayney may publish in the future.

Co-authorship network of co-authors of Douglas W. Blayney

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas W. Blayney. A scholar is included among the top collaborators of Douglas W. Blayney based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas W. Blayney. Douglas W. Blayney is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Automated patient selection and care coaches to increase advance care planning for patients with cancer 2024 ·JNCI Journal of the National Cancer Institute ·Michael F. Gensheimer, Winifred Teuteberg, Manali I. Patel, Divya Gupta, (unknown), (unknown), (unknown), (unknown), Ying Lü, (unknown), (unknown), (unknown), Jan C. DeNofrio, (unknown), Nigam H. Shah, Tai C. Chen, Elwyn C. Cabebe, Douglas W. Blayney, A. Dimitrios Colevas, Kavitha Ramchandran	3
2	Predicting Depression Risk in Patients With Cancer Using Multimodal Data: Algorithm Development Study 2024 ·JMIR Medical Informatics ·Anne de Hond, Marieke van Buchem, (unknown), (unknown), Douglas W. Blayney, Ilse Kant, Ewout W. Steyerberg, Tina Hernandez‐Boussard	10
3	Computing the Cost of Care per Patient per Day for Patients With Metastatic Neuroendocrine Neoplasms 2023 ·JCO Oncology Practice ·Divya Gupta, James I. Barnes, Feifei Qin, Kristopher Kapphahn, (unknown), Douglas W. Blayney, Pamela L. Kunz	1
4	Engagement of Patients with Advanced Cancer (EPAC) randomized clinical trial: Long-term effects on survival and healthcare use. 2023 ·Journal of Clinical Oncology ·Manali I. Patel, (unknown), (unknown), Douglas W. Blayney, Steve Asch, M. Kate Bundorf, Arnold Milstein	1
5	Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model 2021 ·JCO Oncology Practice ·Joel W. Neal, (unknown), (unknown), Christopher Sharp, (unknown), (unknown), Eben L. Rosenthal, Douglas W. Blayney, (unknown), (unknown), Kavitha Ramchandran	10
6	Headache outcomes of a sleep behavioral intervention in breast cancer survivors: Secondary analysis of a randomized clinical trial 2021 ·Cancer ·Yohannes W. Woldeamanuel, Douglas W. Blayney, Booil Jo, (unknown), Catherine Benedict, Ingrid Oakley‐Girvan, Shelli R. Kesler, Oxana Palesh	3
7	1708P Severe neutropenia (grade 4, Gr4N) as a population-based predictor for adverse clinical outcome of chemotherapy induced neutropenia (CIN) 2021 ·Annals of Oncology ·Ramon Mohanlal, Stephan Ogenstad, Lynn L. H. Huang, Douglas W. Blayney	1
8	Cortical Brain Age from Pre-treatment to Post-chemotherapy in Patients with Breast Cancer 2020 ·Neurotoxicity Research ·Ashley M. Henneghan, Vikram Rao, Rebecca A. Harrison, Meghan Karuturi, Douglas W. Blayney, Oxana Palesh, Shelli R. Kesler	26
9	Predicting Patient Reported Outcomes of Cognitive Function Using Connectome-Based Predictive Modeling in Breast Cancer 2019 ·Brain Topography ·Ashley M. Henneghan, Chris Sidey‐Gibbons, Rebecca A. Harrison, (unknown), Vikram Rao, Douglas W. Blayney, Oxana Palesh, Shelli R. Kesler	12
10	P1.01-11 Quality of Life in NSCLC Patients Treated with Docetaxel and Either Plinabulin or Pegfilgrastim for Prevention of Neutropenia 2019 ·Journal of Thoracic Oncology ·Douglas W. Blayney, D. Mitchell, (unknown), Li‐Min Huang, Ramon Mohanlal	1
11	Comparison of orthogonal NLP methods for clinical phenotyping and assessment of bone scan utilization among prostate cancer patients 2019 ·Journal of Biomedical Informatics ·Jean Coquet, Selen Bozkurt, (unknown), (unknown), Douglas W. Blayney, James D. Brooks, Tina Hernandez‐Boussard	16
12	P1.01-06 Plinabulin, a Novel Immuno-Oncology Agent Mitigates Docetaxel Chemotherapy -Induced-Neutropenia and -Thrombocytopenia in NSCLC Patients 2018 ·Journal of Thoracic Oncology ·Douglas W. Blayney, Stephan Ogenstad, Yuankai Shi, Q. Zhang, Liang Du, Li‐Min Huang, Ramon Mohanlal	2
13	Breast cancer treatment across health care systems: Linking electronic medical records and state registry data to enable outcomes research 2013 ·Cancer ·Allison W. Kurian, Aya Mitani, Manisha Desai, Peter Paul Yu, Tina Seto, Susan Weber, Cliff Olson, (unknown), Scarlett Lin Gomez, (unknown), Kathleen C. Horst, Jeffrey Belkora, Suepattra G. May, Dominick L. Frosch, Douglas W. Blayney, Harold S. Luft, Amar K. Das	47
14	Continued Use of Trastuzumab Beyond Disease Progression in the National Comprehensive Cancer Network: Should We Practice Ahead of the Evidence? 2011 ·The Oncologist ·Yu‐Ning Wong, Rebecca A. Ottesen, Melissa E. Hughes, Joyce C. Niland, Richard L. Theriault, Stephen B. Edge, Douglas W. Blayney, Jane C. Weeks	7
15	Lymphoma After Solid Organ Transplantation: Risk, Response to Therapy, and Survival at a Transplantation Center 2009 ·Journal of Clinical Oncology ·Jason S. Knight, Alexander Tsodikov, Diane M. Cibrik, Charles W. Ross, Mark Kaminski, Douglas W. Blayney	132
16	Hypoxia-Inducible Factor-1 Target Genes as Indicators of Tumor Vessel Response to Vascular Endothelial Growth Factor Inhibition 2008 ·Cancer Research ·Duyen T. Dang, Sang Y. Chun, Kyunghee Burkitt, Masako Abe, Shaowei Chen, Pamela A. Havre, Nicola J. Mabjeesh, Elisabeth I. Heath, Nicholas J. Vogelzang, Marcia Cruz‐Correa, Douglas W. Blayney, William D. Ensminger, Brad St. Croix, Nam H. Dang, Long H. Dang	62
17	High-risk germ cell tumors in men high response rate and severe toxicity with cisplatin, vinblastine, bleomycin, and etoposide 1993 ·Cancer ·Douglas W. Blayney, David A. Goldberg, Lucille Leong, Kim Margolin, Jerome S. Burke, James H. Doroshow	8
18	High doses of prochlorperazine for cisplatin-induced emesis: A prospective, random, dose–response study 1987 ·Cancer ·Brian I. Carr, Douglas W. Blayney, David A. Goldberg, Patricia S. Braly, Gerald E. Metter, James H. Doroshow	19
19	Ovarian cancer: epidemiology, diagnosis, and management. 1983 ·PubMed ·Douglas W. Blayney, Dan L. Longo	3
20	Evidence for human T cell lymphoma-leukemia virus infection of family members of human T cell lymphoma-leukemia virus positive T cell leukemia-lymphoma patients. 1983 ·The Journal of Experimental Medicine ·Marjorie Robert-Guroff, V. S. Kalyanaraman, William A. Blattner, M Popovic, M. G. Sarngadharan, M Maeda, Douglas W. Blayney, D Catovsky, Paul A. Bunn, Akira Shibata, Y Nakao, Yôhei Itô, Tadao Aoki, Robert C. Gallo	92

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact